 |
|
Myopericarditis Following Smallpox Vaccination Among Vaccinia-Naive US Military Personnel
Jeffrey S. Halsell, DO;
James R. Riddle, DVM, MPH;
J. Edwin Atwood, MD;
Pierce Gardner, MD;
Robert Shope, MD;
Gregory A. Poland, MD;
Gregory C. Gray, MD, MPH;
Stephen Ostroff, MD;
Robert E. Eckart, DO;
Duane R. Hospenthal, MD, PhD;
Roger L. Gibson, DVM, PhD;
John D. Grabenstein, RPh, PhD;
Mark K. Arness, MD, MTM&;
David N. Tornberg, MD, MPH; and the Department of Defense Smallpox Vaccination Clinical Evaluation Team
JAMA. 2003;289:3283-3289.
Context In the United States, the annual incidence of myocarditis is estimated at 1 to 10 per 100 000 population. As many as 1% to 5% of patients with acute viral infections involve the myocardium. Although many viruses have been reported to cause myopericarditis, it has been a rare or unrecognized event after vaccination with the currently used strain of vaccinia virus (New York City Board of Health).
Objective To describe a series of probable cases of myopericarditis following smallpox vaccination among US military service members reported since the reintroduction of vaccinia vaccine.
Design, Setting, Participants Surveillance case definitions are presented. The cases were identified either through sentinel reporting to US military headquarters surveillance using the Defense Medical Surveillance System or reports to the Vaccine Adverse Event Reporting System using International Classification of Diseases, Ninth Revision. The cases occurred among individuals vaccinated from mid-December 2002 to March 14, 2003.
Main Outcome Measure Elevated serum levels of creatine kinase (MB isoenzyme), troponin I, and troponin T, usually in the presence of ST-segment elevation on electrocardiogram and wall motion abnormalities on echocardiogram.
Results Among 230 734 primary vaccinees, 18 cases of probable myopericarditis after smallpox vaccination were reported (an incidence of 7.8 per 100 000 over 30 days). No cases of myopericarditis following smallpox vaccination were reported among 95 622 vaccinees who were previously vaccinated. All cases were white men aged 21 years to 33 years (mean age, 26.5 years), who presented with acute myopericarditis 7 to 19 days following vaccination. A causal relationship is supported by the close temporal clustering (7-19 days; mean, 10.5 days following vaccination), wide geographic and temporal distribution, occurrence in only primary vaccinees, and lack of evidence for alternative etiologies or other diseases associated with myopericarditis. Additional supporting evidence is the observation that the observed rate of myopericarditis among primary vaccinees is 3.6-fold (95% confidence interval, 3.33-4.11) higher than the expected rate among personnel who were not vaccinated. The background incidence of myopericarditis did not show statistical significance when stratified by age (20-34 years: 2.18 expected cases per 100 000; 95% confidence interval [CI], 1.90-2.34), race (whites: 1.82 per 100 000; 95% CI, 1.50-2.01), and sex (males: 2.28 per 100 000; 95% CI, 2.04-2.54).
Conclusion Among US military personnel vaccinated against smallpox, myopericarditis occurred at a rate of 1 per 12 819 primary vaccinees. Myopericarditis should be considered an expected adverse event associated with smallpox vaccination. Clinicians should consider myopericarditis in the differential diagnosis of patients presenting with chest pain 4 to 30 days following smallpox vaccination and be aware of the implications as well as the need to report this potential adverse advent.
Author Affiliations: The University of Virginia, Charlottesville (Dr Halsell); Office of the Assistant Secretary of Defense for Health Affairs, Falls Church, Va (Drs Riddle, Gibson, and Tornberg); Walter Reed Army Medical Center, Washington, DC (Dr Atwood); Military Vaccine Agency, US Army Medical Command, Falls Church, Va (Dr Grabenstein); National Institutes of Health, Fogarty International Center, Bethesda, Md (Dr Gardner); College of Public Health, University of Iowa, Iowa City (Dr Gray); University of Texas Medical Branch, Center for Tropical Disease, Department of Pathology, Galveston (Dr Shope); National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Ga (Dr Ostroff); Mayo Clinic and Foundation, Rochester, Minn (Dr Poland), Brooke Army Medical Center, Fort Sam Houston, Tex (Drs Eckart and Hospenthal); Army Medical Surveillance Activity, Washington, DC (Dr Arness).
RELATED ARTICLES
US Military Smallpox Vaccination Program Experience
John D. Grabenstein and William Winkenwerder, Jr
JAMA. 2003;289(24):3278-3282.
ABSTRACT
| FULL TEXT
Focal and Generalized Folliculitis Following Smallpox Vaccination Among Vaccinia-Naive Recipients
Thomas R. Talbot, H. Keipp Bredenberg, Michael Smith, Bonnie J. LaFleur, Alan Boyd, and Kathryn M. Edwards
JAMA. 2003;289(24):3290-3294.
ABSTRACT
| FULL TEXT
Response to Smallpox Vaccine in Persons Immunized in the Distant Past
Sharon E. Frey, Frances K. Newman, Lihan Yan, and Robert B. Belshe
JAMA. 2003;289(24):3295-3299.
ABSTRACT
| FULL TEXT
Smallpox Immunization in the 21st Century: The Old and the New
Mary E. Wright and Anthony S. Fauci
JAMA. 2003;289(24):3306-3308.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Myopericarditis versus viral or idiopathic acute pericarditis
Imazio et al.
Heart 2008;94:498-501.
ABSTRACT
| FULL TEXT
Development of Smallpox Vaccine Candidates with Integrated Interleukin-15 That Demonstrate Superior Immunogenicity, Efficacy, and Safety in Mice
Perera et al.
J. Virol. 2007;81:8774-8783.
ABSTRACT
| FULL TEXT
Human Cytotoxic CD4+ T Cells Recognize HLA-DR1-Restricted Epitopes on Vaccinia Virus Proteins A24R and D1R Conserved among Poxviruses
Mitra-Kaushik et al.
J. Immunol. 2007;179:1303-1312.
ABSTRACT
| FULL TEXT
Dominance and Diversity in the Primary Human CD4 T Cell Response to Replication-Competent Vaccinia Virus
Jing et al.
J. Immunol. 2007;178:6374-6386.
ABSTRACT
| FULL TEXT
Task Force II: Indirect and Secondary Cardiovascular Effects of Biological Terrorism Agents and Diseases
Ornato et al.
J Am Coll Cardiol 2007;49:1389-1397.
FULL TEXT
Task Force IV: Cardiovascular Effects of Emerging Infectious Diseases and Biological Terrorism Threats: Basic, Clinical, and Population Science Research and Training Needs
Madjid et al.
J Am Coll Cardiol 2007;49:1407-1412.
FULL TEXT
Chemical-Biological Terrorism and Its Impact on Children
Committee on Environmental Health and Committee on
Pediatrics 2006;118:1267-1278.
ABSTRACT
| FULL TEXT
Immunization to Protect the US Armed Forces: Heritage, Current Practice, and Prospects
Grabenstein et al.
Epidemiol Rev 2006;28:3-26.
ABSTRACT
| FULL TEXT
LC16m8, a Highly Attenuated Vaccinia Virus Vaccine Lacking Expression of the Membrane Protein B5R, Protects Monkeys from Monkeypox.
Saijo et al.
J. Virol. 2006;80:5179-5188.
ABSTRACT
| FULL TEXT
Myocarditis: Current Trends in Diagnosis and Treatment
Magnani and Dec
Circulation 2006;113:876-890.
FULL TEXT
Peptide Mimetics of Gamma Interferon Possess Antiviral Properties against Vaccinia Virus and Other Viruses in the Presence of Poxvirus B8R Protein
Ahmed et al.
J. Virol. 2005;79:5632-5639.
ABSTRACT
| FULL TEXT
Cautious interpretation of data regarding myopericarditis associated with smallpox vaccination
Gami et al.
J Am Coll Cardiol 2005;45:160-160.
FULL TEXT
Reply
Cassimatis et al.
J Am Coll Cardiol 2005;45:160-161.
FULL TEXT
Update in Infectious Diseases
Lorber
ANN INTERN MED 2004;141:875-881.
FULL TEXT
Bioterrorism and compulsory vaccination: United States continues vaccinating to keep troops healthy
Grabenstein and Winkenwerder
BMJ 2004;329:977-977.
FULL TEXT
Myopericarditis following Smallpox Vaccination
Arness et al.
Am J Epidemiol 2004;160:642-651.
ABSTRACT
| FULL TEXT
Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination
Eckart et al.
J Am Coll Cardiol 2004;44:201-205.
ABSTRACT
| FULL TEXT
Safety of the Smallpox Vaccine Among Military Recipients--Reply
Grabenstein et al.
JAMA 2003;290:2124-2124.
FULL TEXT
Safety of the Smallpox Vaccine Among Military Recipients
Nass
JAMA 2003;290:2123-2124.
FULL TEXT
Smallpox Vaccine Safety
JWatch Infect. Diseases 2003;2003:1-1.
FULL TEXT
Some Answers to Smallpox Vaccination Questions
JWatch General 2003;2003:1-1.
FULL TEXT
US Military Smallpox Vaccination Program Experience
Grabenstein and Winkenwerder
JAMA 2003;289:3278-3282.
ABSTRACT
| FULL TEXT
Smallpox Immunization in the 21st Century: The Old and the New
Wright and Fauci
JAMA 2003;289:3306-3308.
FULL TEXT
|
